Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD
Ocular Therapeutix has announced accelerated timelines for its SOL-1 Phase 3 registrational clinical trial of AXPAXLI in wet age-related macular degeneration (wet AMD). The company now expects:
- Full enrollment and randomization by the end of 2024
- Topline data during the fourth quarter of 2025
SOL-1 is a superiority study conducted under a Special Protocol Agreement with the FDA, aiming to randomize approximately 300 subjects. The primary endpoint is the proportion of subjects maintaining visual acuity at Week 36. The ongoing Phase 3 clinical program, including SOL-1 and SOL-R studies, is expected to form the basis for AXPAXLI's regulatory filing for wet AMD treatment.
Ocular Therapeutix ha annunciato un'accelerazione delle tempistiche per il suo trial clinico registrativo SOL-1 di Fase 3 di AXPAXLI per la degenerazione maculare legata all'età umida (wet AMD). L'azienda ora prevede:
- Completamento dell'arruolamento e randomizzazione entro la fine del 2024
- Dati preliminari nel quarto trimestre del 2025
SOL-1 è uno studio di superiorità condotto sotto un Accordo di Protocollo Speciale con la FDA, con l'obiettivo di randomizzare circa 300 soggetti. L'endpoint principale è la proporzione di soggetti che mantengono l'acuità visiva alla settimana 36. Il programma clinico di Fase 3 in corso, che include gli studi SOL-1 e SOL-R, dovrebbe costituire la base per la richiesta regolatoria di AXPAXLI per il trattamento della wet AMD.
Ocular Therapeutix ha anunciado una aceleración en los plazos para su ensayo clínico registrativo SOL-1 de Fase 3 de AXPAXLI en la degeneración macular relacionada con la edad húmeda (wet AMD). La compañía ahora espera:
- Completar la inscripción y la aleatorización para finales de 2024
- Datos preliminares durante el cuarto trimestre de 2025
SOL-1 es un estudio de superioridad realizado bajo un Acuerdo de Protocolo Especial con la FDA, con el objetivo de aleatorizar aproximadamente 300 sujetos. El criterio principal de valoración es la proporción de sujetos que mantienen la agudeza visual a la semana 36. El programa clínico en fase 3 en curso, que incluye los estudios SOL-1 y SOL-R, se espera que forme la base para la presentación regulatoria de AXPAXLI para el tratamiento de la wet AMD.
Ocular Therapeutix는 습식 노인성 황반변성(wet AMD) 치료를 위한 AXPAXLI의 SOL-1 3상 등록 임상 시험의 일정 단축을 발표했습니다. 회사는 이제 다음과 같은 일정으로 예상하고 있습니다:
- 2024년 말까지 전체 모집 및 무작위 배정 완료
- 2025년 4분기에 주요 데이터 공개
SOL-1은 FDA와의 특별 프로토콜 협약에 따라 수행되는 우수성 연구로, 약 300명의 피험자를 무작위로 배정할 예정입니다. 주요 목표는 36주차에 시력 유지 비율입니다. SOL-1 및 SOL-R 연구를 포함한 진행 중인 3상 임상 프로그램은 AXPAXLI의 습식 AMD 치료를 위한 규제 제출의 기초가 될 것으로 예상됩니다.
Ocular Therapeutix a annoncé des délais accélérés pour son essai clinique registratif SOL-1 de phase 3 d'AXPAXLI dans la dégénérescence maculaire liée à l'âge humide (wet AMD). La société s'attend désormais à :
- Un recrutement et une randomisation complets d'ici la fin de 2024
- Des données préliminaires au cours du quatrième trimestre 2025
SOL-1 est une étude de supériorité réalisée dans le cadre d'un Accord de Protocole Spécial avec la FDA, visant à randomiser environ 300 sujets. L'objectif principal est la proportion de sujets maintenant leur acuité visuelle à la semaine 36. Le programme clinique de phase 3 en cours, comprenant les études SOL-1 et SOL-R, devrait constituer la base du dépôt réglementaire pour AXPAXLI pour le traitement de la wet AMD.
Ocular Therapeutix hat beschleunigte Zeitpläne für seine SOL-1 Phase 3 registrierte klinische Studie von AXPAXLI bei feuchter altersbedingter Maculadegeneration (wet AMD) bekannt gegeben. Das Unternehmen erwartet nun:
- Vollständige Rekrutierung und Randomisierung bis Ende 2024
- Erste Daten im vierten Quartal 2025
SOL-1 ist eine Überlegenheitsstudie, die unter einem besonderen Protokollvereinbarung mit der FDA durchgeführt wird, mit dem Ziel, etwa 300 Probanden zu randomisieren. Der primäre Endpunkt ist der Anteil der Probanden, die ihre Sehschärfe in der 36. Woche aufrechterhalten. Das laufende klinische Programm der Phase 3, zu dem SOL-1 und SOL-R Studien gehören, wird voraussichtlich die Grundlage für die regulatorische Einreichung von AXPAXLI zur Behandlung von wet AMD bilden.
- Accelerated timeline for SOL-1 trial completion, with full enrollment expected by end of 2024
- Topline data from SOL-1 trial now expected in Q4 2025, earlier than previously anticipated
- Strong interest from investigators and patients in AXPAXLI's potential to alter wet AMD treatment
- Over 100 clinical trial sites activated for SOL-1, indicating strong research infrastructure
- Increasing momentum in clinical trials, potentially bringing the product closer to market
- None.
Insights
The acceleration of the SOL-1 trial for AXPAXLI in wet AMD is a significant development. Completing enrollment by end of 2024, ahead of schedule, indicates strong interest from both investigators and patients. This could potentially bring a new treatment option to market sooner than expected.
Key points to consider:
- SOL-1 is a superiority study comparing AXPAXLI to aflibercept, a current standard of care
- The trial design, with a Special Protocol Agreement with the FDA, strengthens the regulatory pathway
- Primary endpoint focuses on maintaining visual acuity at Week 36
- If successful, SOL-1 and SOL-R studies could form the basis for regulatory filing
The potential for AXPAXLI to reduce treatment burden in wet AMD patients is particularly noteworthy. Current treatments often require frequent injections and a more durable option could significantly improve patient quality of life and treatment adherence.
This news is likely to be viewed positively by investors for several reasons:
- Accelerated timeline: Faster enrollment could lead to earlier market entry if the drug is successful, potentially accelerating revenue generation
- Strong demand: Rapid enrollment suggests high interest from the medical community, which could translate to strong adoption if approved
- Market opportunity: Wet AMD is a large and growing market, with current treatments generating
billions in annual sales - Competitive positioning: If AXPAXLI demonstrates superiority to aflibercept, it could capture significant market share
However, investors should note that the topline data is still over a year away (Q4 2025) and success is not guaranteed. The company's ability to fund operations until potential approval and launch will be crucial. Overall, this update reduces timeline risk and increases confidence in the program's execution, which should be viewed favorably for Ocular Therapeutix's valuation.
SOL-1 is now expected to be enrolled and fully randomized by year-end 2024
Topline clinical data from SOL-1 are now expected in Q4 2025
BEDFORD, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced accelerated timelines for the SOL-1 Phase 3 registrational clinical trial of AXPAXLI in wet age-related macular degeneration (wet AMD). The Company now expects the SOL-1 study to be fully enrolled with all patients randomized by the end of 2024. This is meaningfully ahead of prior guidance to complete enrollment by the end of the first quarter of 2025. With this update, topline data from the SOL-1 trial are now expected during the fourth quarter of 2025.
SOL-1 is a superiority study being conducted under a Special Protocol Agreement (SPA) with the U.S. Food and Drug Administration (FDA). Once a subject is enrolled in the study, they receive two loading doses of aflibercept (2 mg), one at Week -8 and another at Week -4. Subjects who achieve pre-defined visual acuity measures are then randomized (1:1) on Day 1 to receive either a single AXPAXLI implant (450 µg) or a single aflibercept (2 mg) injection. The Company plans to randomize approximately 300 subjects in the trial. The primary endpoint is the proportion of subjects who maintain visual acuity, defined as <15 ETDRS letters of best corrected visual acuity (BCVA) loss, at Week 36.
Ocular expects the ongoing Phase 3 clinical program, comprised of the SOL-1 superiority study and SOL-R repeat-dosing non-inferiority study, if successfully completed, would form the basis of the Company’s regulatory filing for AXPAXLI for the treatment of wet AMD.
“Thanks to our phenomenal team and their relentless dedication, we are thrilled to announce the acceleration of our timeline for SOL-1, which is now expected to complete randomization by the end of 2024. With this update, we can now confirm that we expect topline data to be available during the fourth quarter of 2025,” said Pravin U. Dugel, MD, Executive Chairman, President and Chief Executive Officer of Ocular Therapeutix. “The exceptional pace of SOL-1 recruitment reflects the strong continued interest from investigators and patients in AXPAXLI’s potential to significantly alter the wet AMD treatment paradigm. In total, the Ocular team activated over 100 clinical trial sites for SOL-1, and we are extremely grateful for the continued high-quality collaboration of our outstanding study sites. We are especially proud to provide this update given the initial perception that SOL-1 was going to be a difficult trial to enroll. Based on our feedback to date, there is even stronger enthusiasm to enroll patients in our repeat dosing study, SOL-R, and we believe the strength of our clinical team will be instrumental to the execution of both trials. This increasing momentum brings us closer to our goal of improving the lives of patients suffering from wet AMD.”
David A. Eichenbaum, MD, FASRS, Director of Research, Retina Vitreous Associates of Florida commented, “Patients with wet AMD need treatment options that offer more durable improvements in visual outcomes. SOL-1 enrollment has advanced at such a rapid pace because AXPAXLI is seeking to directly address this critical unmet need, offering the promise of a significantly reduced treatment burden. SOL-1 and SOL-R are thoughtfully designed complementary trials, which have the potential to deliver meaningful insights on durability, repeat dosing, and comparability to standard-of-care treatment, while meeting FDA regulatory requirements. With SOL-1 soon to complete randomization, I am excited to now enroll patients in SOL-R. I believe patients in the SOL-R study will take comfort in knowing they are receiving an active treatment, regardless of which arm they are randomized to, while the study design mitigates the risk of unmasking from sham injections. I have enjoyed collaborating with the new clinical team at Ocular, whose dedication to patient care, regulatory alignment, and commitment to optimizing the clinical trial process creates an exceptional experience for patients and investigators. Assuming successful trial outcomes and approval, AXPAXLI would offer the promise of a durable treatment option without compromising the rigorous standards for safety and efficacy that the retina community has come to expect.”
About AXPAXLI
AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI) is an investigational, bioresorbable, hydrogel implant incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic properties, being evaluated for the treatment of wet AMD, diabetic retinopathy, and other retinal diseases.
About the SOL-1 Study
The registrational Phase 3 SOL-1 trial (NCT06223958) is designed to evaluate the safety and efficacy of AXPAXLI in a multi-center, double-masked, randomized (1:1), parallel group study that involves sites located in the U.S. and Argentina. The trial is intended to randomize approximately 300 evaluable treatment-naïve subjects with a diagnosis of wet AMD in the study eye.
The superiority study has an eight-week loading segment prior to randomization, a 9-month treatment segment, and a safety follow-up. During the loading segment, subjects who have 20/80 vision or better and who satisfy other enrollment criteria receive two doses of aflibercept (at Week -8 and Week -4). Eligible subjects who achieve best corrected visual acuity (BCVA) of 20/20 at Day 1 or gain at least 10 early treatment diabetic retinopathy (ETDRS) letters at Day 1 are then randomized to receive a single dose of AXPAXLI or a single dose of aflibercept and assessed monthly for the duration of the study. The clinical trial protocol requires that, during the study, subjects in any arm meeting pre-specified rescue criteria will receive a supplemental dose of aflibercept.
The primary endpoint of SOL-1 is the proportion of subjects who maintain visual acuity, defined as a loss of <15 ETDRS letters of BCVA, at Week 36. The study is being conducted under a Special Protocol Agreement (SPA) with the FDA.
About the SOL-R Study
The registrational Phase 3 SOL-R trial (NCT06495918) is designed to evaluate the safety and efficacy of AXPAXLI in a multi-center, double-masked, randomized (2:2:1), three-arm study that will involve sites located in the U.S. and the rest of the world. The trial is intended to randomize approximately 825 subjects who are treatment-naïve or were diagnosed with wet AMD in the study eye within three months prior to enrollment.
The non-inferiority study reflects a patient enrichment strategy that includes multiple loading doses of aflibercept and monitoring to exclude subjects with significant retinal fluid fluctuations. Subjects in the first arm receive a single dose of AXPAXLI at Day 1 and are re-dosed at Week 24. Subjects in the second arm receive aflibercept (2 mg) on-label every 8 weeks. Subjects in the third arm receive a single dose of aflibercept (8 mg) at Day 1 and are re-dosed at Week 24, aligned with the AXPAXLI treatment arm for adequate masking. Subjects in any arm that meet pre-specified rescue criteria will receive a supplemental dose of aflibercept.
The primary endpoint of SOL-R is non-inferiority in mean BCVA change from baseline between the AXPAXLI and on-label aflibercept (2 mg) arms at one year. In a written Type C response received in August 2024, the FDA agreed that the SOL-R repeat dosing wet AMD study is appropriate as an adequate and well-controlled study in support of a potential New Drug Application and product label.
About Wet AMD
Wet age-related macular degeneration (wet AMD) is a leading cause of severe, irreversible vision loss affecting approximately 14 million individuals globally and 1.65 million in the United States alone (2023 Market Scope® Retinal Pharmaceuticals Market Report). Wet AMD causes vision loss due to abnormal new blood vessel growth and hyperpermeability and associated retinal vascularity in the macula, which is primarily stimulated by local upregulation of vascular endothelial growth factor (VEGF). Without prompt and continuous treatment to control this exudative activity, patients develop irreversible vision loss. With proper treatment, patients may maintain visual function for a period of time and may temporarily regain lost vision. Challenges with current therapies include pulsatile, repeated intraocular injections, treatment-related adverse events and up to
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions. AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral implant or OTX-TIC), which has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.
Follow the Company on its website, LinkedIn, or X.
The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Forward-Looking Statements
Any statements in this press release about future expectations, plans, and prospects for the Company, including the development and regulatory status of the Company’s product candidates; the timing, design, and enrollment of the Company’s SOL-1 and SOL-R Phase 3 clinical trials of AXPAXLI (also called OTX-TKI) for the treatment of wet AMD; the Company’s plans to advance the development of AXPAXLI and its other product candidates; the potential utility of any of the Company’s product candidates; and other statements containing the words “anticipate”, “believe”, “estimate”, “expect”, “intend”, “goal”, “may”, “might”, “plan”, “predict”, “project”, “target”, “potential”, “will”, “would”, “could”, “should”, “continue”, and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s preclinical and clinical development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the timing and costs involved in commercializing any product or product candidate that receives regulatory approval; the ability to retain regulatory approval of any product or product candidate that receives regulatory approval; the initiation, design, timing, conduct and outcomes of ongoing and planned clinical trials; the risk that the FDA will not agree with the Company’s interpretation of the written agreement under the Special Protocol Assessment for the SOL-1 trial; the risk that the FDA may not agree that the protocol and statistical analysis plan of SOL-R or the data generated by the SOL-1 and SOL-R trials support marketing approval, even if the trials are successful; uncertainty as to whether the data from earlier clinical trials will be predictive of the data of later clinical trials, particularly later clinical trials that have a different design or utilize a different formulation than the earlier trials, whether preliminary or interim data from a clinical trial will be predictive of final data from such trial, or whether data from a clinical trial assessing a product candidate for one indication will be predictive of results in other indications; availability of data from clinical trials and expectations for regulatory submissions and approvals; the Company’s scientific approach and general development progress; uncertainties inherent in estimating the Company’s cash runway, future expenses and other financial results, including its ability to fund future operations, including clinical trials; the Company’s existing indebtedness and the ability of the Company’s creditors to accelerate the maturity of such indebtedness upon the occurrence of certain events of default; and other factors discussed in the “Risk Factors” section contained in the Company’s quarterly and annual reports on file with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments may cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
FAQ
What is the new timeline for Ocular Therapeutix's SOL-1 trial for AXPAXLI (OCUL)?
How many subjects will be randomized in the SOL-1 trial for AXPAXLI (OCUL)?
What is the primary endpoint of the SOL-1 trial for AXPAXLI (OCUL)?